Publications

467 publications

Enter search criteria

Keyword

Fill in keyword(s) to narrow your search.

Period

Last 7 days Last 30 days Last 365 days Specific period

Period from

The start date was not recognised. Please enter the date in the following format: DD-MM-YYYY.

Period up to

The end date was not recognised. Please enter the date in the following format: DD-MM-YYYY.

The end date may not occur before the start date.

Type

You can select a specific type of a publication you are looking for, such as press releases or speeches

Sort by:

Date
Relevance

Preferential policy towards biological drugs

CVZ regards biological drugs as therapeutically interchangeable if they are designated as "similar" after being registered by the ...

Report | 26-09-2011
Eslicarbazepine (Zebinix) for the ‘adjunctive treatment of partial onset seizures with or without secondary generalisation in adults with epilepsy’

The therapeutic value of eslicarbazepine as an adjunctive treatment for partial epilepsy is comparable with that of ...

Report | 26-09-2011
Apixaban (Eliquis) for the prevention of venous thromboembolic events

For the prevention of venous thromboembolic events in adults after a hip or knee replacement operation apixaban has an added ...

Report | 26-09-2011
Descriptions of pharmaceutical care provisions 2012 (BR/CU- 5056) – clarification within the framework of health insurance.

The Dutch Healthcare Authority (Nederlandse Zorgautoriteit, NZa) has approved a new ‘Descriptions of pharmaceutical care ...

Report | 29-08-2011
PCA3 medical test as diagnostic intervention for prostate cancer

CVZ has examined whether using the PCA3 gene expression test on patients with suspected prostate cancer and a negative initial ...

Report | 22-08-2011
Indications for proton therapy

Proton therapy is regarded as an insured provision for the indications head/neck tumours, breast cancer, lung cancer and prostate ...

Report | 22-08-2011
Ranibizumab (Lucentis) for the treatment of visual impairment due to diabetic macular oedema

Head-to-head trials have shown that, with respect to the intended and unintended effects, ranibizumab is superior to laser for ...

Report | 25-07-2011
Atomoxetine (Strattera) for the treatment of Attention Deficit Hyperactivity Disorder

The Medicinal Products Reimbursement Committee (CFH) has carried out a re-assessment of the medicine atomoxetine (Strattera). ...

Report | 27-06-2011
Lapatinib (Tyverb) in combination with an aromatase inhibitor for the indication metastatic HR+ HER2+ breast cancer

For postmenopausal patients with HR+ HER2+ metastatic breast cancer without rapid progression, without extensive visceral ...

Report | 27-06-2011
Amifampridine (Firdapse) for the symptomatic treatment of Lambert Eaton myasthenic syndrome (LEMS)

For the treatment of LEMS, amifampridine phosphate has an added therapeutic value in comparison with pyridostigmine. For the ...

Report | 27-06-2011

Publications

467 publications

Preferential policy towards biological drugs

Eslicarbazepine (Zebinix) for the ‘adjunctive treatment of partial onset seizures with or without secondary generalisation in adults with epilepsy’

Apixaban (Eliquis) for the prevention of venous thromboembolic events

Descriptions of pharmaceutical care provisions 2012 (BR/CU- 5056) – clarification within the framework of health insurance.

PCA3 medical test as diagnostic intervention for prostate cancer

Indications for proton therapy

Ranibizumab (Lucentis) for the treatment of visual impairment due to diabetic macular oedema

Atomoxetine (Strattera) for the treatment of Attention Deficit Hyperactivity Disorder

Lapatinib (Tyverb) in combination with an aromatase inhibitor for the indication metastatic HR+ HER2+ breast cancer

Amifampridine (Firdapse) for the symptomatic treatment of Lambert Eaton myasthenic syndrome (LEMS)

Go to